Business
Know the Business
Molina is a pure-play government managed care organization — a regulated spread business that collects a fixed monthly fee per enrolled member from state Medicaid agencies and CMS and takes the risk of paying those members' medical bills. In good years the retained slice is 4-5 cents on the premium dollar; in 2025 it was 1.7 cents. That swing — driven by medical cost inflation outrunning state rate updates — is the lens for every other fact in this report.
FY25 Premium Revenue ($M)
FY25 Net Income ($M)
FY25 Medical Care Ratio
FY25 Pre-tax Margin
Members (M)
States
Medicaid % of Premium
Market Cap ($M)
The verdict. Molina is a mid-quality, cyclically-mispriced business, not a high-quality compounder. It earns 20-30% ROE in good years on a tiny single-digit operating margin — a feat of capital efficiency that depends on premium revenue 10x book value and a regulator that keeps rates "actuarially sound." It has scale (5.5M members, $45B revenue), real RFP-execution skill, and a clean Medicaid focus. It has no vertical integration moat, no pricing power, and no defense against a regulator that runs late on rates. The investment case is essentially: is 2025-26 a cyclical trough that re-rates back to mid-teens earnings power, or has the structural margin profile of pure-play Medicaid stepped down for good?
1. The economic engine in one chart
Strip away segments, states, and acquisitions: Molina collects roughly $655/month per member, pays ~$600 to providers, spends ~$45 on administration, and keeps what's left. The variance in "what's left" is the entire P&L.
A 260 bp jump in the Medical Care Ratio between 2024 and 2025 erased $926M of operating income ($1,707M → $781M) and 60% of net income ($1,179M → $472M; -56% on diluted EPS) — no SG&A explosion, no failed product, no goodwill writedown. MCR is the master variable. Every 100 bps is worth ~$430M of pre-tax income (~$6+ of EPS at the current share count); almost everything else is a second-order driver.
Why this is not just "any insurance company." A property & casualty insurer holds reserves for years and earns most of its return on the float. MOH receives a capitation payment monthly, in advance of paying claims, and pays out the bulk within 30-60 days. There is some float (medical claims payable was $4.9B at end-2025), but the business is structurally an operating spread, not an investment spread. Investment income contributed only $420M (0.9% of revenue) in FY25. The operating margin is the entire game.
2. Twenty years of the same spread — at growing scale
Two superimposed patterns: a 27x revenue scale-up over twenty years (states migrating Medicaid into managed care, MOH winning more contracts), and around it a 3-5 year MCR cycle that compresses margins 200-500 bps before states catch rates up to cost trends.
Molina has grown almost every year, with step-changes from ACA Medicaid expansion (2014-15) and the Marketplace acquisitions of 2020-22. The operating-margin chart is where the cycle is visible. Three full cycles:
2007-2012: the post-financial-crisis Medicaid rate-lag cycle. Margins compressed from 3.9% to 0.7%, then partially recovered.
2017 (the canonical disaster): a Marketplace re-pricing miss plus a Medicaid acuity shock produced an outright operating loss of $555M and a stock that fell 60%. The recovery — once new management priced Marketplace correctly and a new Medicaid cycle hit — produced a 6.0% operating margin by 2018 and an EPS run-rate that tripled within two years.
2024-2026 (now): the OBBBA + ACA-subsidy + redetermination shock running on top of an industry-wide utilization wave. Margins compressed from 4.2% to 1.7% in a single year.
The 2017 episode is the most instructive piece of MOH's history: proof the current management team has lived through a trough, and proof 2025-26 is not MOH-specific.
3. Three product lines, three pricing cycles
One consolidated MCR hides three economically distinct businesses under one license. A reader who treats them as one line item will miss almost everything.
4. Where the members are — and the geographic concentration nobody pictures
5.49M members across 21 states sounds diversified. On revenue, four states do most of the work.
The concentration trade-off. State-by-state contracting is both the moat and the risk. Once embedded, renewal win rates exceed 90% (MOH retained $14B across 2019-2025 re-procurements). But every 3-5 years each state goes back out to bid. A single Texas loss would be 5%+ of consolidated premium and a multi-quarter EPS event. Investors should never confuse "21 states" with "diversified." The right mental model is "Texas + California + Washington + New York + an option portfolio on 17 smaller states."
5. The return profile — capital-light but spread-driven
MOH's total assets are $15.6B against $4.1B of shareholder equity, with most of that asset base held against medical claims payable ($4.9B). The business needs little capital to grow, which is why ROE in good years runs 25-30% on a sub-3% net margin.
The 2018-24 ROE band of 27-47% is the cycle-on case. The current 11% is half of mid-cycle and entirely a function of MCR. The DuPont here is not leverage-driven (equity multiplier ~3.8x, normal for an insurer); the high return comes from asset turns (revenue is 3x assets) on a normal margin. Only the margin has compressed.
Cash flow does NOT track earnings here, and 2025 was particularly noisy. OCF went from +$644M in 2024 to −$535M in 2025 despite $472M of net income. The swing is almost entirely government-receivable timing — Medicaid minimum-MLR settlements, medical-cost-corridor true-ups, Marketplace risk-adjustment payables, and tax timing. Q1 2026 alone produced +$1,082M of OCF as those receivables normalised. Treat full-year OCF as multi-year-smoothed; do not annualise any single quarter or year, and do not extrapolate the 2025 print as a deterioration.
6. Capital allocation — what management actually does with the money
The capital story is straightforward and consistent over the last six years:
The 2025 buyback math is uncomfortable. Management bought back roughly $500M in Q1 2025 at an average of about $294/share (1.7M shares per the FY25 10-K) and roughly $500M in Q3 2025 at about $179/share (2.8M shares). The stock closed at $200.28 on June 12, 2026. The Q1 2025 tranche is materially underwater; the Q3 tranche is roughly $20/share above purchase cost. This is not a unique judgment failure — most insurers struggle to time buybacks across the MCR cycle — but it is a meaningful drag on per-share book value compounding for shareholders who held through.
The parent's cash buffer is thin. Cash at the parent fell to $223M by end-2025 from $445M a year prior, after funding ConnectiCare, $1B of buybacks, and capital injections into subs. Subsidiary dividends to parent ($985M in 2025) are expected to decline in 2026 on lower 2025 net income. The credit-facility amendment in February 2026 (temporarily lowering the minimum Interest Coverage Ratio to 1.75x for 2026 vs the standard 3.0x) tells you covenants are tight in this cycle. Investors should track parent-level liquidity quarter by quarter.
7. The moat question — what actually keeps competitors out
No Buffett-style moat. A portfolio of operational advantages that compound at the state level but are continually contested:
The honest read. MOH's competitive advantage is operational discipline applied to a regulated cycle — not a structural moat. It is consistently lean (6.6% G&A vs 7-9% at diversified peers), it has decades of pattern-recognition for Medicaid RFP design, and it has the courage to walk away from mis-priced business (2017 Marketplace exit, 2026 Marketplace and MAPD retrenchment). Those traits earn the company a 27% mid-cycle ROE but they do not earn it a premium multiple — because none of those traits is durable against a state agency that decides to award next cycle's contract to a competitor.
8. The peer arena — Centene is the mirror, UnitedHealth is the benchmark
MOH is the smallest, the cheapest, the most government-exposed, and the second-most-leveraged of the six listed managed-care names to a pure Medicaid cycle.
Three observations:
MOH and CNC trade at a 7-8x EV/Revenue discount to UNH. Part is justified — UNH's revenue dollar carries Optum services and PBM margins. The gap is what the bull case is built on.
CNC is the cautionary tale. Centene's LTM net income is −$6.4B after a Marketplace risk-adjustment miss. The bear case is "this could be you next quarter" — and MOH's 90.6% Marketplace MCR vs CNC's wipeout is the cleanest contrast between the two right now.
MOH's 55x P/E is meaningless on trough earnings. At mid-cycle EPS of $20-22 (the 2023-24 range), the stock trades at ~9x. Bears say that's reasonable for a no-moat cyclical; bulls say the multiple has already de-rated.
9. The 2026 setup — what we know, what is guided, what is at stake
Q1 2026 has been reported. The year's shape is now visible.
2026 guidance is further compression, not recovery. GAAP EPS guided to at least $1.90 (after a $93M MAPD impairment in Q1) and adjusted EPS to at least $5.00 — roughly an 80% drop from the $24.50 starting 2025 guide ($24.50 → $5.00). The ~$3B premium decline is structural: the deliberate Marketplace retreat (~$2.3B walked away from to restore margin) plus Medicaid contraction from Virginia and continued redeterminations.
Q1 2026 prints support the guide and suggest stabilisation rather than further breakdown:
- Consolidated MCR 91.1% — 60 bps lower than FY25 full-year
- Medicaid MCR 92.0% — "moderately favourable" to expectations on the Jan 1 rate cycle
- Medicare MCR 89.8% — in-line, reflecting 2026 benefit re-design
- Marketplace MCR 84.0% — or ~79.5% ex prior-year noise, close to target
- Operating cash flow +$1.08B — government-receivable timing fully normalised
- Management held the guide and pointed to an Investor Day on May 8, 2026 for the three-year outlook
The path back to mid-cycle earnings. State Medicaid rate cycles take 12-24 months from cost-trend recognition to rate adjustment. Cost trends were elevated through 2024 and 2025; the 2026 rate cycle is the first rate-setting period that fully reflects that. If Medicaid MCR can move back to 89-90% by 2027 — and Medicare/Marketplace stay near target — operating income normalises to roughly $2.0-2.5B on the $50B premium base management targets. That implies $25-30 of EPS run-rate on a share count that buybacks will likely have shrunk further. The cycle math is the entire bull case. It is contingent on state legislatures funding higher capitation rates, on continued utilization moderation, and on OBBBA implementation not removing more Medicaid Expansion members than priced in.
10. The valuation lens — pick your scenario
On trough earnings (FY25 actual or FY26 guide), every multiple is distorted: P/E 22-55x, P/B 2.2x, EV/Sales 0.11x. On normalised earnings the picture inverts.
The right valuation lens is "through-cycle P/E on normalised EPS." Use EV/EBITDA on a 3-year trailing average as a cross-check (currently ~7x on trailing, ~5-6x on normalised), and look at price/tangible book (~5.6x) as a downside floor — though tangible book is small ($1.9B) because $2.2B sits in goodwill from acquisitions. Do not use EV/Revenue alone — the 0.11x optical print invites apples-to-oranges comparisons with diversified peers and obscures that MOH's revenue dollar is structurally the thinnest in the listed payer set.
Through-cycle, MOH has earned $18-22 of EPS in 2022-24 with capital discipline and 27-30% ROE. The buy-side debate today is whether those earnings come back at all (bear case: structural step-down in Medicaid economics) or whether they come back stronger (bull case: the 2026 rate cycle restores margin and the deliberate Marketplace pruning is permanent). The right answer determines whether the current $200 quote is a 6x or a 15x stock.
11. The eight numbers an investor must track each quarter
These are the metrics that move the stock:
12. The one-page conclusion
What MOH is. A pure-play government MCO selling operational discipline to state Medicaid agencies and CMS. 75% Medicaid, 21 states, 5.5M members, $43B premium. A regulated spread: ~92¢ to providers, ~7¢ to admin, ~1¢ to keepers in a bad year and 4-5¢ in a good year.
What it isn't. Not a vertically integrated services company (UNH/Optum), not a diversified payer (ELV/CVS), not a Star-Ratings-driven MA specialist (HUM). The "moat" is operational excellence in a regulated cycle — real, but not durable against a state agency that picks a different bidder.
Why it's interesting now. The MCR cycle compressed earnings ~60% in one year and the multiple ~50% from late-2024 highs. Centene's blow-up has tainted the pure-play government segment. The setup is a Medicaid rate-cycle trade on a 12-24 month horizon, anchored on the pattern that states eventually fund higher capitation. Bulls underwrite $25-30 EPS by 2027-28; bears underwrite a structural margin step-down from OBBBA, redetermination effects, and renewed national-plan competition.
The right lens. Through-cycle P/E on normalised EPS ($18-22), cross-checked against trailing-average EV/EBITDA and price-to-tangible-book as a downside floor. Spot earnings and single-year EV/Revenue are misleading in this part of the cycle.
The single number that determines the outcome. Consolidated MCR. Back to 88-90% by 2027 supports the bull case; sustained above 91% confirms the bear case and today's 11% ROE as the new normal.